Key points interpretation of <i>Expert consensus on clinical diagnosis and treatment path of retinal vein occlusion in China</i>_Chinese Journal of Ocular Fundus Diseases

Authors：

 Li Xiaoxin ^1,2

1. Xiamen Eye Center of Xiamen University, Xiamen 361003, China;
2. Department of Ophthalmology, Peking University People’s Hospital, Beijing 100044, China;

Corresponding?author：

Li Xiaoxin, Email: dr_lixiaoxin@163.com

Keywords：

Retinal vein occlusion; Anterior segment neovascularization; Neovascular glaucoma; Macular edema; Anti-vascular endothelial growth factor drug therapy; Laser photocoagulation; Consensus interpretation

DOI：

10.3760/cma.j.cn511434-20240320-00113

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Retinal vein occlusion (RVO) is a closely related disease of ophthalmology and systemic diseases. The Expert consensus on clinical diagnosis and treatment path of retinal vein occlusion in China (consensus) emphasizes that etiological diagnosis and treatment should be paid primary attention to, and etiological exploration should be placed in an important position in the diagnosis and treatment path. In addition to etiological treatment, the consensus emphasizes that clinical attention should be paid to the management of anterior segment neovascularization, neovascular glaucoma and macular edema. Especially for patients with short course of central retinal vein occlusion, the occurrence of 100-day glaucoma should be vigilant, and active anti-vascular endothelial growth factor (VEGF) drugs, laser photocoagulation and intraocular pressure treatment should be taken. For the treatment of macular edema, the consensus points out that anti-VEGF drugs and intraocular glucocorticoid sustained-release agents are effective, but the latter should be used cautiously to avoid problems such as high intraocular pressure glaucoma and accelerated cataract formation. For deficient RVO, the consensus defines its concept, defines the time point of treatment when combined with macular edema, and clarifies the applicable conditions of laser therapy.

Citation： Li Xiaoxin. Key points interpretation of Expert consensus on clinical diagnosis and treatment path of retinal vein occlusion in China. Chinese Journal of Ocular Fundus Diseases, 2024, 40(4): 264-267. doi: 10.3760/cma.j.cn511434-20240320-00113 Copy

1.	Driban M, Kedia N, Arora S, et al. Novel pharmaceuticals for the management of retinal vein occlusion and linked disorders[J]. Expert Rev Clin Pharmacol, 2023, 16(11): 1125-1139. DOI: 10.1080/17512433.2023.2277882.
2.	安寧, 楊相穎, 張福燕, 等. 視網膜靜脈阻塞的藥物治療進展[J]. 世界臨床藥物, 2021, 42(4): 314-320. DOI: 10.13683/j.wph.2021.04.015.An N, Yang XY, Zhang FY, et al. Progress in medication treatment of retinal vein occlusion[J]. World Clinical Drugs, 2021, 42(4): 314-320. DOI: 10.13683/j.wph.2021.04.015.
3.	中華醫學會眼科學分會眼底病學組, 中國醫師協會眼科醫師分會眼底病專業委員會. 中國視網膜靜脈阻塞臨床診療路徑專家共識[J]. 中華眼底病雜志, 2024, 40(3): 175-185. DOI: 10.3760/cma.j.cn511434-20240201-00056.Fundus Diseases Group in Ophthalmology Branch of Chinese Medical Association, Professional Committee of Fundus Diseases in Ophthalmology Branch of Chinese Medical Doctor Association. Expert consensus on clinical diagnosis and treatment path of retinal vein occlusion in China[J]. Chin J Ocul Fundus Dis, 2024, 40(3): 175-185. DOI: 10.3760/cma.j.cn511434-20240201-00056.
4.	Gass A. Central retinal venous obstruction[M]//Gass A. Gass’Atlas of macular diseases. 5th eds. Holand: Academic Press, Elsevier, 2011: 588.
5.	Jaulim A, Ahmed B, Khanam T, et al. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature[J]. Retina, 2013, 33(5): 901-910. DOI: 10.1097/IAE.0b013e3182870c15.
6.	Rong AJ, Swaminathan SS, Vanner EA, et al. Predictors of neovascular glaucoma in central retinal vein occlusion[J]. Am J Ophthalmol, 2019, 204: 62-69. DOI: 10.1016/j.ajo.2019.02.038.
7.	Ryu CL, Elfersy A, Desai U, et al. The effect of antivascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: a retrospective analysis[J/OL]. J Ophthalmol, 2014, 2014: 317694[2014-04-01]. https://pubmed.ncbi.nlm.nih.gov/24800060/. DOI: 10.1155/2014/317694.
8.	李水, 楊華靜, 代家樂, 等. 視網膜靜脈阻塞機制及危險因素研究進展[J]. 國際眼科雜志, 2024, 24(1): 72-76. DOI: 10.3980/j.issn.1672-5123.2024.1.14.Li S, Yang HJ, Dai JL, et al. Research progress of mechanism and risk factors of retinal vein occlusion[J]. Int Eye Sci, 2024, 24(1): 72-76. DOI: 10.3980/j.issn.1672-5123.2024.1.14.
9.	Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study[J]. Ophthalmology, 2014, 121(1): 209-219. DOI: 10.1016/j.ophtha.2013.08.038.
10.	Lashay A, Riazi-Esfahani H, Mirghorbani M, et al. Intravitreal medications for retinal vein occlusion: systematic review and meta-analysis[J]. J Ophthalmic Vis Res, 2019, 14(3): 336-366. DOI: 10.18502/jovr.v14i3.4791.
11.	Massa H, Georgoudis P, Panos GD. Dexamethasone intravitreal implant (OZURDEX?) for macular edema secondary to noninfectious uveitis: a review of the literature[J]. Ther Deliv, 2019, 10(6): 343-351. DOI: 10.4155/tde-2019-0024.
12.	Flaxel CJ, Adelman RA, Bailey ST, et al. Retinal vein occlusions preferred practice pattern?[J]. Ophthalmology, 2020, 127(2): 288-320. DOI: 10.1016/j.ophtha.2019.09.029.
13.	Berger AR, Cruess AF, Altomare F, et al. Optimal treatment of retinal vein occlusion: Canadian expert consensus[J]. Ophthalmologica, 2015, 234(1): 6-25. DOI: 10.1159/000381357.
14.	Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase Ⅲ study[J]. Ophthalmology, 2010, 117(6): 1102-1112. DOI: 10.1016/j.ophtha.2010.02.021.
15.	Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase Ⅲ study[J]. Ophthalmology, 2011, 118(10): 2041-2049. DOI: 10.1016/j.ophtha.2011.02.038.
16.	Li X, Wang N, Liang X, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study[J]. Graefe's Arch Clin Exp Ophthalmol, 2018, 256(1): 59-69. DOI: 10.1007/s00417-017-3831-6.
17.	Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA)[J]. Ophthalmologica, 2019, 242(3): 123-162. DOI: 10.1159/000502041.
18.	Hayreh SS. Photocoagulation for retinal vein occlusion[J/OL]. Prog Retin Eye Res, 2021, 85: 100964[2021-03-11]. https://pubmed.ncbi.nlm.nih.gov/33713810/. DOI: 10.1016/j.preteyeres.2021.100964.
19.	The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion[J]. Ophthalmology, 1995, 102(10): 1434-1444. DOI: 10.1016/S0161-6420(95)30848-2.
20.	Khayat M, Williams M, Lois N. Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion[J]. Surv Ophthalmol, 2018, 63(6): 816-850. DOI: 10.1016/j.survophthal.2018.04.005.
21.	An W, Han J. Research progress of UWFFA and OCTA in retinal vein occlusion: a review[J]. Eur J Ophthalmol, 2021, 31(6): 2850-2855. DOI: 10.1177/11206721211027411.
22.	Tsai G, Banaee T, Conti FF, et al. Optical coherence tomography angiography in eyes with retinal vein occlusion[J]. J Ophthalmic Vis Res, 2018, 13(3): 315-332. DOI: 10.4103/jovr.jovr_264_17.

1. Driban M, Kedia N, Arora S, et al. Novel pharmaceuticals for the management of retinal vein occlusion and linked disorders[J]. Expert Rev Clin Pharmacol, 2023, 16(11): 1125-1139. DOI: 10.1080/17512433.2023.2277882.
2. 安寧, 楊相穎, 張福燕, 等. 視網膜靜脈阻塞的藥物治療進展[J]. 世界臨床藥物, 2021, 42(4): 314-320. DOI: 10.13683/j.wph.2021.04.015.An N, Yang XY, Zhang FY, et al. Progress in medication treatment of retinal vein occlusion[J]. World Clinical Drugs, 2021, 42(4): 314-320. DOI: 10.13683/j.wph.2021.04.015.
3. 中華醫學會眼科學分會眼底病學組, 中國醫師協會眼科醫師分會眼底病專業委員會. 中國視網膜靜脈阻塞臨床診療路徑專家共識[J]. 中華眼底病雜志, 2024, 40(3): 175-185. DOI: 10.3760/cma.j.cn511434-20240201-00056.Fundus Diseases Group in Ophthalmology Branch of Chinese Medical Association, Professional Committee of Fundus Diseases in Ophthalmology Branch of Chinese Medical Doctor Association. Expert consensus on clinical diagnosis and treatment path of retinal vein occlusion in China[J]. Chin J Ocul Fundus Dis, 2024, 40(3): 175-185. DOI: 10.3760/cma.j.cn511434-20240201-00056.
4. Gass A. Central retinal venous obstruction[M]//Gass A. Gass’Atlas of macular diseases. 5th eds. Holand: Academic Press, Elsevier, 2011: 588.
5. Jaulim A, Ahmed B, Khanam T, et al. Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature[J]. Retina, 2013, 33(5): 901-910. DOI: 10.1097/IAE.0b013e3182870c15.
6. Rong AJ, Swaminathan SS, Vanner EA, et al. Predictors of neovascular glaucoma in central retinal vein occlusion[J]. Am J Ophthalmol, 2019, 204: 62-69. DOI: 10.1016/j.ajo.2019.02.038.
7. Ryu CL, Elfersy A, Desai U, et al. The effect of antivascular endothelial growth factor therapy on the development of neovascular glaucoma after central retinal vein occlusion: a retrospective analysis[J/OL]. J Ophthalmol, 2014, 2014: 317694[2014-04-01]. https://pubmed.ncbi.nlm.nih.gov/24800060/. DOI: 10.1155/2014/317694.
8. 李水, 楊華靜, 代家樂, 等. 視網膜靜脈阻塞機制及危險因素研究進展[J]. 國際眼科雜志, 2024, 24(1): 72-76. DOI: 10.3980/j.issn.1672-5123.2024.1.14.Li S, Yang HJ, Dai JL, et al. Research progress of mechanism and risk factors of retinal vein occlusion[J]. Int Eye Sci, 2024, 24(1): 72-76. DOI: 10.3980/j.issn.1672-5123.2024.1.14.
9. Campochiaro PA, Sophie R, Pearlman J, et al. Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study[J]. Ophthalmology, 2014, 121(1): 209-219. DOI: 10.1016/j.ophtha.2013.08.038.
10. Lashay A, Riazi-Esfahani H, Mirghorbani M, et al. Intravitreal medications for retinal vein occlusion: systematic review and meta-analysis[J]. J Ophthalmic Vis Res, 2019, 14(3): 336-366. DOI: 10.18502/jovr.v14i3.4791.
11. Massa H, Georgoudis P, Panos GD. Dexamethasone intravitreal implant (OZURDEX?) for macular edema secondary to noninfectious uveitis: a review of the literature[J]. Ther Deliv, 2019, 10(6): 343-351. DOI: 10.4155/tde-2019-0024.
12. Flaxel CJ, Adelman RA, Bailey ST, et al. Retinal vein occlusions preferred practice pattern?[J]. Ophthalmology, 2020, 127(2): 288-320. DOI: 10.1016/j.ophtha.2019.09.029.
13. Berger AR, Cruess AF, Altomare F, et al. Optimal treatment of retinal vein occlusion: Canadian expert consensus[J]. Ophthalmologica, 2015, 234(1): 6-25. DOI: 10.1159/000381357.
14. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase Ⅲ study[J]. Ophthalmology, 2010, 117(6): 1102-1112. DOI: 10.1016/j.ophtha.2010.02.021.
15. Campochiaro PA, Brown DM, Awh CC, et al. Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase Ⅲ study[J]. Ophthalmology, 2011, 118(10): 2041-2049. DOI: 10.1016/j.ophtha.2011.02.038.
16. Li X, Wang N, Liang X, et al. Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study[J]. Graefe's Arch Clin Exp Ophthalmol, 2018, 256(1): 59-69. DOI: 10.1007/s00417-017-3831-6.
17. Schmidt-Erfurth U, Garcia-Arumi J, Gerendas BS, et al. Guidelines for the management of retinal vein occlusion by the European Society of Retina Specialists (EURETINA)[J]. Ophthalmologica, 2019, 242(3): 123-162. DOI: 10.1159/000502041.
18. Hayreh SS. Photocoagulation for retinal vein occlusion[J/OL]. Prog Retin Eye Res, 2021, 85: 100964[2021-03-11]. https://pubmed.ncbi.nlm.nih.gov/33713810/. DOI: 10.1016/j.preteyeres.2021.100964.
19. The Central Vein Occlusion Study Group. A randomized clinical trial of early panretinal photocoagulation for ischemic central vein occlusion[J]. Ophthalmology, 1995, 102(10): 1434-1444. DOI: 10.1016/S0161-6420(95)30848-2.
20. Khayat M, Williams M, Lois N. Ischemic retinal vein occlusion: characterizing the more severe spectrum of retinal vein occlusion[J]. Surv Ophthalmol, 2018, 63(6): 816-850. DOI: 10.1016/j.survophthal.2018.04.005.
21. An W, Han J. Research progress of UWFFA and OCTA in retinal vein occlusion: a review[J]. Eur J Ophthalmol, 2021, 31(6): 2850-2855. DOI: 10.1177/11206721211027411.
22. Tsai G, Banaee T, Conti FF, et al. Optical coherence tomography angiography in eyes with retinal vein occlusion[J]. J Ophthalmic Vis Res, 2018, 13(3): 315-332. DOI: 10.4103/jovr.jovr_264_17.

Chinese Journal of Ocular Fundus Diseases

Key points interpretation of Expert consensus on clinical diagnosis and treatment path of retinal vein occlusion in China

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content